{"id":3278,"date":"2018-05-18T03:20:48","date_gmt":"2018-05-18T08:20:48","guid":{"rendered":"https:\/\/issels.com\/blog\/?p=3278"},"modified":"2018-04-29T13:26:29","modified_gmt":"2018-04-29T18:26:29","slug":"superblood-engineered-to-carry-cancer-fighting-proteins","status":"publish","type":"post","link":"https:\/\/issels.com\/blog\/2018\/05\/18\/superblood-engineered-to-carry-cancer-fighting-proteins\/","title":{"rendered":"“Superblood” Engineered to Carry Cancer Fighting Proteins"},"content":{"rendered":"
\""Superblood"
“Superblood” Engineered to Carry Cancer Fighting Proteins<\/figcaption><\/figure>\n

Super powers are usually the stuff of comic books and movies, but a biotech startup may be turning fiction into reality with the development of “superblood”<\/a> as a revolutionary new cancer treatment<\/a>.<\/p>\n

“Supercharging” Red Blood Cells<\/strong><\/p>\n

Rubius Therapeutics is working on a program called Red-Cell Therapeutics (RCT), which involves red blood cells<\/a> that are genetically engineered to fight cancer. Once introduced into a patient’s system, these proteins can replace missing enzymes and help the immune system attack and destroy cancer cells.<\/p>\n

RCT has two major advantages that make it a promising breakthrough in cancer treatment:<\/p>\n

– The nuclei have been removed from these cells so they can’t be recognized by the immune system<\/a>, leaving them free from interference so they can do their job.<\/p>\n

– Red blood cells travel throughout the entire body, so RCT is able to easily reach any affected organs or tissues.<\/p>\n

Thanks to these two features, RCT has the potential to treat patients without the need for an individually developed solution.<\/p>\n

What’s Next?<\/strong><\/p>\n

Initially, Rubius Therapeutics generated $120 million from investors. The company recently raised an additional $100 million for a total of nearly a quarter of a billion dollars in less than one year. According to Rubius president Torben Straight Nissen, this funding will help accelerate RCT development for quicker delivery to the end users.<\/p>\n

Issels\u00ae: The Leader in Immunotherapy Cancer Treatments<\/strong><\/p>\n

Much like RCT, cancer treatment at Issels\u00ae is designed to boost the immune system’s ability to attack and kill cancer cells. Contact us<\/a> to learn more about cancer vaccines<\/a> and other programs we have used to help patients achieve long-term remission.<\/p>\n","protected":false},"excerpt":{"rendered":"

Super powers are usually the stuff of comic books and movies, but a biotech startup may be turning fiction into reality with the development of “superblood” as a revolutionary new cancer treatment. “Supercharging” Red Blood Cells Rubius Therapeutics is working on a program called Red-Cell Therapeutics (RCT), which involves red blood cells that are genetically … Continue reading “Superblood” Engineered to Carry Cancer Fighting Proteins<\/span> →<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[202,203,580,216,538,2],"tags":[222,229,438,282,219,287,694],"class_list":["post-3278","post","type-post","status-publish","format-standard","hentry","category-alternative-cancer-treatment","category-cancer-research","category-cancer-treatment","category-immunotherapy","category-immunotherapy-for-cancer","category-news","tag-advanced-cancer-research","tag-advanced-cancer-treatment","tag-blood-treatment","tag-cancer-news","tag-immunotherapy","tag-new-cancer-treatment","tag-super-blood-treatment"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/3278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/comments?post=3278"}],"version-history":[{"count":2,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/3278\/revisions"}],"predecessor-version":[{"id":3284,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/3278\/revisions\/3284"}],"wp:attachment":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/media?parent=3278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/categories?post=3278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/tags?post=3278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}